Effectiveness of Natalizumab in Relapsing Remitting Multiple Sclerosis: An Observational Study from a Tertiary Referral Tunisian Center

被引：0
|
作者：
Majoul, Mohamed Slim [1 ]
Zouari, Rania [1 ]
Becha, Mariem [1 ]
Rachdi, Amine [1 ]
Saied, Mohamed Zakaria [1 ]
Ben Mohamed, Dina [1 ]
Ben Sassi, Samia [1 ]
机构：
[1] Natl Inst Mongi Ben Hmida Neurol, Dept Neurol, Tunis, Tunisia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1679/1016
引用
收藏
页码：1061 / 1062
页数：2
相关论文
共 50 条
  • [21] Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
    Kerbrat, A.
    Le Page, E.
    Leray, E.
    Anani, T.
    Coustans, M.
    Desormeaux, C.
    Guiziou, C.
    Kassiotis, P.
    Lallement, F.
    Laplaud, D.
    Diraison, P.
    Rouhart, F.
    Sartori, E.
    Wardi, R.
    Wiertlewski, S.
    Edan, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 308 (1-2) : 98 - 102
  • [22] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
    Baroncini, D.
    Ghezzi, A.
    Stefanin, C.
    Zaffaroni, M.
    Annovazzi, P.
    Baldini, S.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
  • [23] Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
    Sangalli, F.
    Moiola, L.
    Bucello, S.
    Annovazzi, P.
    Rizzo, A.
    Radaelli, M.
    Vitello, G.
    Grimaldi, L. M. E.
    Ghezzi, A.
    Martinelli, V.
    Comi, G.
    NEUROLOGICAL SCIENCES, 2011, 31 : S299 - S302
  • [24] A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
    Trojano, Maria
    Ramio-Torrenta, Lluis
    Grimaldi, Luigi M. E.
    Lubetzki, Catherine
    Schippling, Sven
    Evans, Karleyton C.
    Ren, Zheng
    Muralidharan, Kumar Kandadi
    Licata, Stephanie
    Gafson, Arie R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2240 - 2253
  • [25] Natalizumab for relapsing-remitting multiple sclerosis: interim data from the Ireland Tysabri Observational Program (iTOP)
    Mcguigan, C.
    Ryan, A.
    Sweeney, B.
    Murphy, S. M.
    Mccabe, D.
    Kinirons, P.
    Murphy, K.
    Hutchinson, M.
    Hanna, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 762 - 763
  • [26] Natalizumab reduces cortical pathology in relapsing–remitting multiple sclerosis
    Nature Reviews Neurology, 2012, 8 (7) : 355 - 355
  • [27] Rituximab following natalizumab withdrawal in relapsing remitting multiple sclerosis
    Beaber, B. E.
    Mallari, G.
    Le, D.
    Langer-Gould, A. M.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 193 - 193
  • [28] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [29] Observational, retrospective study in relapsing-remitting multiple sclerosis to compare the effectiveness of second line treatments Fingolimod and Natalizumab in Spanish clinical practice
    Ricart, Javier
    Duran, Carmen
    Martinez Yelamos, Sergio
    Ayuso, Teresa
    Angel Hernandez, Miguel
    Herrera, Nicolas
    Perez Sempere, Angel
    Garcia, Eli
    Meca Lallana, Jose
    NEUROLOGY, 2018, 90
  • [30] Effectiveness and safety of alemtuzumab in the treatment of active relapsing–remitting multiple sclerosis: a multicenter, observational study
    Gregor Brecl Jakob
    Barbara Barun
    Sarah Gomezelj
    Tereza Gabelić
    Saša Šega Jazbec
    Ivan Adamec
    Alenka Horvat Ledinek
    Uroš Rot
    Magdalena Krbot Skorić
    Mario Habek
    Neurological Sciences, 2021, 42 : 4591 - 4597
12345